http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2598345-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65a5803d54fffcac27c95cd6e9081747 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
| filingDate | 2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0073e912c9afc702a47ebddaa9da6da3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acd186252ed80285395009caf85cf835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_802012f1e81362a858035d106bfe259b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e991f53fa043ef9abf6e34f4310a2f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf0c2f33106a7f6b97f802bca715ddf3 |
| publicationDate | 2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2598345-C2 |
| titleOfInvention | Solid dispersions containing agents causing apoptosis |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to a solid dispersion for apoptosis induction. Dispersion contains a compound of formula I n , n where: R 0 denotes chlorine; R 1 and R 2 denote H; R 3 and R 4 denote methyl; A 1 denotes N and A 2 denotes CH; R 5 denotes nitro; X denotes -NH-; Y denotes -(CH 2 ) n -, where n=1; and R 6 is selected from a group consisting of tetrahydropyranyl and 4-hydroxy-4-methylcyclohexyl; or its pharmaceutically acceptable salt. Herewith the compound of formula I or its pharmaceutically acceptable salt are dispersed in a solid matrix, which contains (a) at least one pharmaceutically acceptable water-soluble polymer carrier and (b) at least one pharmaceutically acceptable surfactant. Water-soluble polymer carrier is selected from a group consisting of homopolymers and copolymers of N-vinillactams, cellulose esters, cellulose ethers, polyalkylene oxides with high molecular weight, polyacrylates, polymethacrylates, polyacrylamides, vinyl acetate polymers, grafted copolymers of ethylene glycol, polyvinyl caprolactam and polyvinyl acetate, oligo- and polysaccharides and mixtures thereof. Surfactant is selected from a group consisting of polyoxyethylene glycerides, monoesters of sorbitan fatty acids, polysorbates, α-tocopheryl-polyethylene glycol succinate (TPGS) and their mixtures. Also not more than 5 % of the compound of formula I or its pharmaceutically acceptable salt in a solid dispersion is in crystalline form as per X-ray diffraction analysis data. Also described are: a method of producing the solid dispersion, orally delivered pharmaceutical dosage form. n EFFECT: solid dispersion is suitable for oral use by a person who needs it for treating a disease characterized by overexpression of one or more antiapoptosis proteins from the Bcl-2 family, for example, cancer. n 44 cl, 2 tbl, 17 ex |
| priorityDate | 2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2400.